Safety and antiviral activity of inhaled siRNA SNS812 for treatment of mild-to-moderate COVID-19: a phase 2 randomized trial
Chen et al., Journal of Biomedical Science, doi:10.1186/s12929-026-01284-5 (results released 3/11/2025)
https://c19early.org/chen52.html